Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
RIGEL PHARMACEUTICALS INC (RIGL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/01/2023 8-K Quarterly results
08/01/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/12/2023 SC 13G/A FMR LLC reports a 0.1% stake in RIGEL PHARMACEUTICALS INC
05/15/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
05/02/2023 8-K Quarterly results
Docs: "Rigel Reports First Quarter 2023 Financial Results and Provides Business Update"
04/14/2023 ARS Form ARS - Annual Report to Security Holders:
04/14/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/07/2023 8-K Quarterly results
Docs: "Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
03/07/2023 10-K Annual Report for the period ended December 31, 2022
02/22/2023 SC 13G Soleus Capital Master Fund, L.P. reports a 5.3% stake in RIGEL PHARMACEUTICALS INC.
02/14/2023 SC 13G GOLDMAN SACHS GROUP INC reports a 5.4% stake in RIGEL PHARMACEUTICALS INC
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 9.8% stake in Rigel Pharmaceuticals, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 5.1% stake in RIGEL PHARMACEUTICALS INC
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7% stake in Rigel Pharmaceuticals Inc.
02/06/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/03/2023 8-K Quarterly results
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/29/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
11/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients"
10/11/2022 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback --Announces Workforce Reduction--"
10/11/2022 SC 13G/A STATE STREET CORP reports a 2.2% stake in EXIT FILING Rigel Pharmaceuticals Inc
10/11/2022 SC 13G/A FMR LLC reports a 9% stake in RIGEL PHARMACEUTICALS INC
09/22/2022 SC 13G MILLENNIUM MANAGEMENT LLC reports a 4.4% stake in RIGEL PHARMACEUTICALS, INC.
08/03/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/02/2022 8-K Quarterly results
Docs: "Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update"
08/02/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/25/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy